Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (84)	8/2/2006 2:14:43 PM
From: Ian@SI	Read Replies (1) \| Respond to of 507

OT EMIS: Oral heparin being tested a few years ago was not a small molecule. That was in Phase IIIs then, CEO obfuscated; luckily I left (with a whole $1/share profit). I still don't trust anything the company says. Nevertheless if their Oral Insulin is ever approved, or becomes quite likely to be approved, I'd expect one of the majors to take them out before they ever sell a single dose. On Topic: I hope you stay in NKTR. Otherwise I'm about to snatch defeat from the jaws of victory. :-(